| Specialized_Centers | GeneMol_Centers | Treatment_Access | Research_Funding | Awareness_Campaigns | Survival_Rates | Early_Detection | Palliative_Care | EGFR | ALK | PD_L1 | MET | ROS1 | BRAF | KRAS | Clinical_Guideline | Feasibility_Integration | Adoption_of_Intl_Guidelines | Engagement_with_Updates | ESMO_Guidelines_Implementation | Reimbursement | No_cost | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mean | 3.357 | 3.286 | 3.381 | 3.024 | 3.381 | 3.286 | 3.071 | 3.357 | 73.000 | 67.238 | 80.000 | 54.071 | 58.786 | 48.500 | 63.643 | 3.714 | 3.333 | 3.333 | 2.024 | 3.333 | 1.690 | 1.667 |
| median | 3.500 | 3.000 | 3.500 | 3.000 | 3.000 | 3.000 | 3.000 | 3.000 | 77.500 | 71.500 | 84.500 | 57.000 | 62.000 | 50.500 | 67.000 | 4.000 | 3.000 | 3.000 | 2.000 | 3.000 | 2.000 | 2.000 |
| std | 1.428 | 1.181 | 1.413 | 1.263 | 1.327 | 1.402 | 1.280 | 1.394 | 15.021 | 14.555 | 12.915 | 13.181 | 13.364 | 13.330 | 14.018 | 1.053 | 1.303 | 1.303 | 0.740 | 1.303 | 1.012 | 1.016 |
| variance | 2.039 | 1.395 | 1.998 | 1.595 | 1.760 | 1.966 | 1.638 | 1.944 | 225.619 | 211.848 | 166.810 | 173.733 | 178.597 | 177.679 | 196.515 | 1.109 | 1.698 | 1.698 | 0.547 | 1.698 | 1.023 | 1.032 |
| min | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 40.000 | 35.000 | 50.000 | 25.000 | 30.000 | 20.000 | 20.000 | 2.000 | 1.000 | 1.000 | 1.000 | 1.000 | 0.000 | 0.000 |
| max | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 | 92.000 | 87.000 | 96.000 | 75.000 | 78.000 | 70.000 | 85.000 | 5.000 | 5.000 | 5.000 | 3.000 | 5.000 | 3.000 | 3.000 |
| skew | -0.300 | -0.306 | -0.339 | 0.026 | -0.416 | -0.153 | 0.003 | -0.285 | -0.805 | -0.810 | -0.964 | -0.661 | -0.733 | -0.650 | -0.937 | -0.267 | -0.117 | -0.117 | -0.038 | -0.117 | -0.319 | -0.252 |
| kurtosis | -1.253 | -0.683 | -1.178 | -0.916 | -0.840 | -1.192 | -0.916 | -1.122 | -0.427 | -0.346 | -0.050 | -0.306 | -0.397 | -0.355 | 0.709 | -1.142 | -1.065 | -1.065 | -1.171 | -1.065 | -0.981 | -1.037 |
| coefficient of variation | 0.425 | 0.359 | 0.418 | 0.418 | 0.392 | 0.427 | 0.417 | 0.415 | 0.206 | 0.216 | 0.161 | 0.244 | 0.227 | 0.275 | 0.220 | 0.284 | 0.391 | 0.391 | 0.365 | 0.391 | 0.598 | 0.609 |
| 75th percentile | 5.000 | 4.000 | 5.000 | 4.000 | 4.750 | 5.000 | 4.000 | 5.000 | 85.000 | 77.750 | 89.750 | 62.750 | 68.000 | 57.750 | 72.750 | 5.000 | 5.000 | 5.000 | 3.000 | 5.000 | 2.000 | 2.000 |
| 50th percentile | 3.500 | 3.000 | 3.500 | 3.000 | 3.000 | 3.000 | 3.000 | 3.000 | 77.500 | 71.500 | 84.500 | 57.000 | 62.000 | 50.500 | 67.000 | 4.000 | 3.000 | 3.000 | 2.000 | 3.000 | 2.000 | 2.000 |
| 25th percentile | 2.000 | 3.000 | 2.000 | 2.000 | 3.000 | 2.000 | 2.000 | 2.250 | 62.750 | 57.750 | 72.750 | 45.500 | 50.500 | 40.500 | 55.750 | 3.000 | 2.250 | 2.250 | 1.250 | 2.250 | 1.000 | 1.000 |
| interquartile range | 3.000 | 1.000 | 3.000 | 2.000 | 1.750 | 3.000 | 2.000 | 2.750 | 22.250 | 20.000 | 17.000 | 17.250 | 17.500 | 17.250 | 17.000 | 2.000 | 2.750 | 2.750 | 1.750 | 2.750 | 1.000 | 1.000 |
| mean | median | std | variance | min | max | skew | kurtosis | coefficient of variation | 75th percentile | 50th percentile | 25th percentile | interquartile range | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malaysia | 3.14 | 3.0 | 0.578 | 0.334 | 2.5 | 4.0 | 0.322 | -1.489 | 0.184 | 3.6 | 3.0 | 2.6 | 1.0 |
| South Africa | 3.00 | 3.0 | 0.276 | 0.076 | 2.7 | 3.5 | 0.859 | -0.500 | 0.092 | 3.0 | 3.0 | 2.8 | 0.2 |
| Kenya | 1.50 | 1.5 | 0.465 | 0.216 | 1.0 | 2.2 | 0.239 | -1.400 | 0.310 | 1.8 | 1.5 | 1.0 | 0.8 |
| Nigeria | 1.48 | 1.5 | 0.435 | 0.190 | 1.0 | 2.1 | 0.121 | -1.529 | 0.294 | 1.8 | 1.5 | 1.0 | 0.8 |
| Egypt | 2.48 | 2.5 | 0.435 | 0.190 | 2.0 | 3.1 | 0.121 | -1.529 | 0.176 | 2.8 | 2.5 | 2.0 | 0.8 |
| Morocco | 2.34 | 2.0 | 0.418 | 0.174 | 2.0 | 2.9 | 0.426 | -1.795 | 0.178 | 2.8 | 2.0 | 2.0 | 0.8 |
| Algeria | 2.10 | 2.0 | 0.310 | 0.096 | 1.8 | 2.7 | 1.251 | -0.005 | 0.148 | 2.0 | 2.0 | 2.0 | 0.0 |
| Ethiopia | 1.22 | 1.0 | 0.349 | 0.122 | 1.0 | 1.9 | 1.332 | -0.013 | 0.286 | 1.2 | 1.0 | 1.0 | 0.2 |
| India | 2.88 | 3.0 | 0.487 | 0.238 | 2.0 | 3.5 | -0.759 | -0.350 | 0.169 | 3.0 | 3.0 | 2.9 | 0.1 |
| Japan | 4.56 | 4.5 | 0.258 | 0.066 | 4.2 | 5.0 | 0.446 | -0.537 | 0.057 | 4.6 | 4.5 | 4.5 | 0.1 |
| South Korea | 4.54 | 4.5 | 0.287 | 0.082 | 4.1 | 5.0 | 0.103 | -0.577 | 0.063 | 4.6 | 4.5 | 4.5 | 0.1 |
| China | 3.48 | 3.5 | 0.319 | 0.102 | 3.0 | 4.0 | 0.182 | -0.554 | 0.092 | 3.5 | 3.5 | 3.4 | 0.1 |
| Thailand | 3.08 | 3.0 | 0.160 | 0.026 | 3.0 | 3.4 | 1.500 | 0.250 | 0.052 | 3.0 | 3.0 | 3.0 | 0.0 |
| Singapore | 4.72 | 5.0 | 0.392 | 0.154 | 4.0 | 5.0 | -1.027 | -0.564 | 0.083 | 5.0 | 5.0 | 4.6 | 0.4 |
| United Kingdom | 4.68 | 5.0 | 0.466 | 0.218 | 3.8 | 5.0 | -1.150 | -0.334 | 0.100 | 5.0 | 5.0 | 4.6 | 0.4 |
| Germany | 4.62 | 4.6 | 0.371 | 0.138 | 4.0 | 5.0 | -0.511 | -0.996 | 0.080 | 5.0 | 4.6 | 4.5 | 0.5 |
| France | 4.56 | 4.6 | 0.476 | 0.226 | 3.7 | 5.0 | -0.865 | -0.573 | 0.104 | 5.0 | 4.6 | 4.5 | 0.5 |
| Netherlands | 4.56 | 4.6 | 0.476 | 0.226 | 3.7 | 5.0 | -0.865 | -0.573 | 0.104 | 5.0 | 4.6 | 4.5 | 0.5 |
| Sweden | 4.54 | 4.6 | 0.512 | 0.262 | 3.6 | 5.0 | -0.946 | -0.472 | 0.113 | 5.0 | 4.6 | 4.5 | 0.5 |
| Italy | 4.04 | 4.0 | 0.403 | 0.162 | 3.6 | 4.5 | 0.074 | -1.752 | 0.100 | 4.5 | 4.0 | 3.6 | 0.9 |
| Spain | 4.02 | 4.0 | 0.426 | 0.182 | 3.5 | 4.5 | 0.017 | -1.724 | 0.106 | 4.5 | 4.0 | 3.6 | 0.9 |
| Poland | 3.30 | 3.5 | 0.276 | 0.076 | 2.8 | 3.5 | -0.974 | -0.666 | 0.084 | 3.5 | 3.5 | 3.2 | 0.3 |
| Mexico | 2.72 | 2.5 | 0.312 | 0.098 | 2.5 | 3.3 | 1.074 | -0.476 | 0.115 | 2.8 | 2.5 | 2.5 | 0.3 |
| Brazil | 3.08 | 3.0 | 0.160 | 0.026 | 3.0 | 3.4 | 1.500 | 0.250 | 0.052 | 3.0 | 3.0 | 3.0 | 0.0 |
| Argentina | 3.08 | 3.0 | 0.160 | 0.026 | 3.0 | 3.4 | 1.500 | 0.250 | 0.052 | 3.0 | 3.0 | 3.0 | 0.0 |
| Chile | 3.06 | 3.0 | 0.120 | 0.014 | 3.0 | 3.3 | 1.500 | 0.250 | 0.039 | 3.0 | 3.0 | 3.0 | 0.0 |
| Colombia | 2.74 | 2.5 | 0.301 | 0.090 | 2.5 | 3.2 | 0.540 | -1.549 | 0.110 | 3.0 | 2.5 | 2.5 | 0.5 |
| United States | 4.72 | 5.0 | 0.392 | 0.154 | 4.0 | 5.0 | -1.027 | -0.564 | 0.083 | 5.0 | 5.0 | 4.6 | 0.4 |
| Canada | 4.60 | 4.6 | 0.405 | 0.164 | 3.9 | 5.0 | -0.650 | -0.833 | 0.088 | 5.0 | 4.6 | 4.5 | 0.5 |
| Australia | 4.48 | 4.5 | 0.387 | 0.150 | 3.8 | 5.0 | -0.595 | -0.434 | 0.086 | 4.6 | 4.5 | 4.5 | 0.1 |
| New Zealand | 4.08 | 4.0 | 0.271 | 0.074 | 3.8 | 4.6 | 1.173 | -0.069 | 0.066 | 4.0 | 4.0 | 4.0 | 0.0 |
| Greece | 3.40 | 3.5 | 0.200 | 0.040 | 3.0 | 3.5 | -1.500 | 0.250 | 0.059 | 3.5 | 3.5 | 3.5 | 0.0 |
| Rwanda | 1.18 | 1.0 | 0.271 | 0.074 | 1.0 | 1.7 | 1.233 | -0.184 | 0.230 | 1.2 | 1.0 | 1.0 | 0.2 |
| Uganda | 1.20 | 1.0 | 0.310 | 0.096 | 1.0 | 1.8 | 1.291 | -0.083 | 0.258 | 1.2 | 1.0 | 1.0 | 0.2 |
| Serbia | 2.98 | 3.0 | 0.098 | 0.010 | 2.8 | 3.1 | -0.868 | -0.271 | 0.033 | 3.0 | 3.0 | 3.0 | 0.0 |
| Saudi Arabia | 3.60 | 3.5 | 0.210 | 0.044 | 3.4 | 4.0 | 1.170 | -0.169 | 0.058 | 3.6 | 3.5 | 3.5 | 0.1 |
| UAE | 3.62 | 3.5 | 0.194 | 0.038 | 3.5 | 4.0 | 1.363 | 0.038 | 0.054 | 3.6 | 3.5 | 3.5 | 0.1 |
| Syria | 1.18 | 1.0 | 0.271 | 0.074 | 1.0 | 1.7 | 1.233 | -0.184 | 0.230 | 1.2 | 1.0 | 1.0 | 0.2 |
| Indonesia | 2.34 | 2.5 | 0.287 | 0.082 | 2.0 | 2.7 | -0.201 | -1.679 | 0.123 | 2.5 | 2.5 | 2.0 | 0.5 |
| Vietnam | 2.56 | 2.5 | 0.338 | 0.114 | 2.0 | 3.0 | -0.398 | -0.873 | 0.132 | 2.8 | 2.5 | 2.5 | 0.3 |
| Philippines | 2.32 | 2.5 | 0.264 | 0.070 | 2.0 | 2.6 | -0.348 | -1.794 | 0.114 | 2.5 | 2.5 | 2.0 | 0.5 |
| Russia | 3.20 | 3.0 | 0.245 | 0.060 | 3.0 | 3.5 | 0.408 | -1.833 | 0.077 | 3.5 | 3.0 | 3.0 | 0.5 |
| id | country | Specialized_Centers | GeneMol_Centers | Treatment_Access | Research_Funding | Awareness_Campaigns | Survival_Rates | Early_Detection | Palliative_Care | EGFR | ALK | PD_L1 | MET | ROS1 | BRAF | KRAS | Clinical_Guideline | Feasibility_Integration | Adoption_of_Intl_Guidelines | Engagement_with_Updates | ESMO_Guidelines_Implementation | Reimbursement | No_cost | Cancer_Screening |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | South Africa | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 60 | 55 | 70 | 45 | 50 | 40 | 55 | 3 | 3 | 3 | 2 | 3 | 1 | 1 | No national LDCT program |
| 1 | Kenya | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 50 | 45 | 60 | 35 | 40 | 30 | 48 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | No national LDCT program |
| 2 | Nigeria | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 48 | 43 | 58 | 33 | 38 | 28 | 45 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | No national LDCT program |
| 3 | Egypt | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 70 | 65 | 78 | 52 | 57 | 47 | 62 | 3 | 3 | 3 | 2 | 3 | 1 | 1 | No national LDCT program |
| 4 | Morocco | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 65 | 60 | 75 | 50 | 55 | 45 | 58 | 3 | 3 | 3 | 2 | 3 | 1 | 1 | No national LDCT program |
| 5 | Algeria | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 60 | 55 | 70 | 45 | 50 | 40 | 55 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | No national LDCT program |
| 6 | Ethiopia | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 45 | 40 | 55 | 30 | 35 | 25 | 42 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | No national LDCT program |
| 7 | India | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 65 | 60 | 75 | 50 | 55 | 45 | 58 | 3 | 2 | 2 | 1 | 2 | 1 | 1 | No national LDCT program |
| 8 | Japan | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 92 | 87 | 96 | 75 | 78 | 70 | 85 | 5 | 5 | 5 | 3 | 5 | 3 | 3 | No national LDCT program |
| 9 | South Korea | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 91 | 86 | 95 | 74 | 77 | 69 | 84 | 5 | 5 | 5 | 3 | 5 | 3 | 3 | LDCT for high-risk individuals (50-74 years) |
| 10 | China | 4 | 4 | 4 | 3 | 4 | 3 | 3 | 4 | 80 | 73 | 85 | 58 | 63 | 53 | 68 | 4 | 3 | 3 | 2 | 3 | 2 | 2 | No national LDCT program |
| 11 | Thailand | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 78 | 70 | 83 | 57 | 62 | 52 | 67 | 4 | 3 | 3 | 2 | 3 | 2 | 2 | No national LDCT program |
| 12 | Singapore | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 89 | 84 | 94 | 72 | 76 | 67 | 82 | 5 | 5 | 5 | 3 | 5 | 2 | 2 | No national LDCT program |
| 13 | United Kingdom | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 85 | 80 | 90 | 65 | 70 | 60 | 75 | 5 | 5 | 5 | 3 | 5 | 3 | 3 | LDCT for high-risk individuals (55-74 years) |
| 14 | Germany | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 89 | 83 | 94 | 69 | 74 | 63 | 79 | 5 | 5 | 5 | 3 | 5 | 3 | 3 | No national program, under evaluation |
| 15 | France | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 86 | 79 | 91 | 64 | 69 | 59 | 74 | 5 | 5 | 5 | 3 | 5 | 3 | 3 | No national LDCT screening |
| 16 | Netherlands | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 85 | 78 | 90 | 63 | 68 | 58 | 73 | 5 | 5 | 5 | 3 | 5 | 3 | 3 | Participating in European screening studies |
| 17 | Sweden | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 84 | 77 | 89 | 62 | 67 | 57 | 72 | 5 | 5 | 5 | 3 | 5 | 3 | 3 | No national LDCT screening |
| 18 | Italy | 5 | 4 | 5 | 4 | 4 | 5 | 4 | 5 | 83 | 76 | 88 | 61 | 66 | 56 | 71 | 4 | 4 | 4 | 2 | 4 | 3 | 3 | Regional pilot LDCT screening |
| 19 | Spain | 5 | 4 | 5 | 4 | 4 | 5 | 4 | 5 | 82 | 75 | 87 | 60 | 65 | 55 | 70 | 4 | 4 | 4 | 2 | 4 | 2 | 2 | No national LDCT program |
| 20 | Poland | 4 | 3 | 4 | 3 | 4 | 3 | 3 | 4 | 75 | 68 | 80 | 55 | 60 | 50 | 65 | 3 | 3 | 3 | 2 | 3 | 2 | 2 | No national program |
| 21 | Mexico | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 2 | 75 | 70 | 82 | 54 | 60 | 50 | 66 | 3 | 3 | 3 | 2 | 3 | 2 | 2 | No national LDCT program |
| 22 | Brazil | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 78 | 73 | 85 | 58 | 63 | 53 | 68 | 4 | 3 | 3 | 2 | 3 | 2 | 2 | No national LDCT program |
| 23 | Argentina | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 77 | 72 | 84 | 57 | 62 | 52 | 67 | 4 | 3 | 3 | 2 | 3 | 2 | 2 | No national LDCT program |
| 24 | Chile | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 76 | 71 | 83 | 56 | 61 | 51 | 66 | 4 | 3 | 3 | 2 | 3 | 2 | 2 | No national LDCT program |
| 25 | Colombia | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 2 | 74 | 69 | 81 | 53 | 59 | 49 | 64 | 4 | 3 | 3 | 2 | 3 | 2 | 2 | No national LDCT program |
| 26 | United States | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 90 | 85 | 95 | 70 | 75 | 65 | 80 | 5 | 5 | 5 | 3 | 5 | 2 | 1 | Annual LDCT (50-80 years, high-risk smokers) |
| 27 | Canada | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 88 | 82 | 93 | 68 | 73 | 62 | 78 | 5 | 5 | 5 | 3 | 5 | 3 | 3 | LDCT for high-risk individuals (55-74 years) |
| 28 | Australia | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 87 | 81 | 92 | 67 | 72 | 61 | 77 | 5 | 5 | 5 | 3 | 5 | 2 | 2 | No national program, high-risk groups advised LDCT |
| 29 | New Zealand | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 86 | 81 | 92 | 67 | 72 | 61 | 77 | 5 | 5 | 5 | 3 | 5 | 2 | 2 | No national LDCT program |
| 30 | Greece | 4 | 3 | 4 | 3 | 4 | 3 | 3 | 4 | 80 | 75 | 87 | 60 | 65 | 55 | 70 | 4 | 3 | 3 | 2 | 3 | 2 | 2 | No national LDCT program |
| 31 | Rwanda | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 40 | 35 | 50 | 25 | 30 | 20 | 38 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | No national LDCT program |
| 32 | Uganda | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 42 | 37 | 52 | 27 | 32 | 22 | 40 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | No national LDCT program |
| 33 | Serbia | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 68 | 63 | 78 | 52 | 57 | 47 | 62 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | No national LDCT program |
| 34 | Saudi Arabia | 4 | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 75 | 70 | 85 | 60 | 65 | 50 | 68 | 4 | 4 | 4 | 2 | 4 | 2 | 2 | No program high-risk CT pilots |
| 35 | UAE | 4 | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 78 | 72 | 88 | 62 | 68 | 55 | 70 | 4 | 4 | 4 | 2 | 4 | 0 | 0 | N/A |
| 36 | Syria | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 40 | 35 | 50 | 25 | 30 | 20 | 38 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | N/A |
| 37 | Indonesia | 2 | 2 | 3 | 2 | 3 | 3 | 2 | 3 | 60 | 55 | 70 | 45 | 50 | 40 | 55 | 3 | 2 | 2 | 1 | 2 | 0 | 0 | N/A |
| 38 | Vietnam | 3 | 3 | 3 | 2 | 3 | 3 | 2 | 3 | 62 | 57 | 72 | 47 | 52 | 42 | 58 | 3 | 2 | 2 | 1 | 2 | 0 | 0 | N/A |
| 39 | Philippines | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 58 | 52 | 68 | 43 | 48 | 38 | 53 | 3 | 2 | 2 | 1 | 2 | 0 | 0 | N/A |
| 40 | Russia | 4 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 80 | 75 | 85 | 60 | 65 | 50 | 70 | 4 | 3 | 3 | 2 | 3 | 0 | 0 | N/A |
| 41 | Malaysia | 4 | 4 | 4 | 3 | 3 | 3 | 2 | 3 | 90 | 75 | 85 | 40 | 35 | 25 | 20 | 4 | 4 | 4 | 2 | 4 | 0 | 0 | N/A |
